PE20001415A1 - Composiciones que tienen suministro mejorado de activos - Google Patents

Composiciones que tienen suministro mejorado de activos

Info

Publication number
PE20001415A1
PE20001415A1 PE2000000017A PE0000172000A PE20001415A1 PE 20001415 A1 PE20001415 A1 PE 20001415A1 PE 2000000017 A PE2000000017 A PE 2000000017A PE 0000172000 A PE0000172000 A PE 0000172000A PE 20001415 A1 PE20001415 A1 PE 20001415A1
Authority
PE
Peru
Prior art keywords
solvent
composition
antihistamines
mol
refers
Prior art date
Application number
PE2000000017A
Other languages
English (en)
Inventor
Kishor Jivanlal Desai
Brian James Robbins
Ii Jerry William Hayes
Douglas Joseph Dobrozsi
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of PE20001415A1 publication Critical patent/PE20001415A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents

Abstract

SE REFIERE A UNA COMPOSICION QUE COMPRENDE: a)5OO gr/mol DE PRINCIPIO ACTIVO QUE SE CARACTERIZA POR TENER UN PORCENTAJE DE VALOR DE SOLUBILIDAD SUPERIOR A 0,075% A 25% EN EL DISOLVENTE A TEMPERATURA AMBIENTE; EN FORMA LIBRE NO IONIZADO CON UNA DISPERSION MONOMOLECULAR EN EL DISOLVENTE; TENER UN PESO MOLECULAR INFERIOR A 500 g/MOL; POR TENER UN COEFICIENTE DE PARTICION OCTANOL-AGUA DE POR LO MENOS 100; TAL COMO ANTITUSIVOS, ANTIHISTAMINAS, ANTIHISTAMINAS NO SEDANTES, DESCONGESTIONANTES EXPECTORANTES, ANALGESICOS, MUCOLITCOS, ANTIINFLAMATORIOS, ANTIPIRETICOS, ENTRE OTROS; DE PREFERENCIA 6,85mg A 30,83mg DE DEXTROMETORFANO; b)DE 60% A 99,97% DE UN DISOLVENTE ANHIDRIDO, HIDROFILO, MISCIBLE EN AGUA TAL COMO PROPILENGLICOL, ETANOL, POLI(ETILENGLICOL), CARBONATO DE PROPILENO, ENTRE OTROS; c)ADEMAS COMPRENDE OTROS AGENTES ACTIVOS TAL COMO PSEUDOEFEDRINA, FENILPROPILAMINA, ACETAMINOFEN, CLORFENIRAMINA, DOXILAMINA, FENINDAMINA, TRIPROLIDINA. LA COMPOSICION PUEDE PRESENTARSE EN FORMA DE CAPSULAS MASTICABLES, GOMAS, ELIXIRES, PASTILLAS, ENTRE OTROS, CON UN RECUBRIMIENTO EXTERIOR QUE COMPRENDE UNA COMPOSICION PARA EL PRETRATAMIENTO DEL TEJIDO MUCOSAL. TAMBIEN SE REFIERE A UN PROCESO PARA LA PREPARACION
PE2000000017A 1999-01-11 2000-01-10 Composiciones que tienen suministro mejorado de activos PE20001415A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11537899P 1999-01-11 1999-01-11

Publications (1)

Publication Number Publication Date
PE20001415A1 true PE20001415A1 (es) 2001-01-05

Family

ID=22361013

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000000017A PE20001415A1 (es) 1999-01-11 2000-01-10 Composiciones que tienen suministro mejorado de activos

Country Status (15)

Country Link
US (1) US6846495B2 (es)
EP (1) EP1140093A2 (es)
JP (1) JP2002534463A (es)
KR (1) KR100511730B1 (es)
CN (1) CN1203854C (es)
AU (1) AU762366B2 (es)
BR (1) BR0007445A (es)
CA (1) CA2356881C (es)
CO (1) CO5270007A1 (es)
CZ (1) CZ20012491A3 (es)
HU (1) HUP0105021A3 (es)
NO (1) NO20013442L (es)
PE (1) PE20001415A1 (es)
TR (1) TR200101927T2 (es)
WO (1) WO2000041693A2 (es)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001066089A2 (en) * 2000-03-09 2001-09-13 Gw Pharma Limited Pharmaceutical compositions comprising cannabis
EP1321140B1 (en) * 2000-08-25 2005-04-06 Kowa Company, Ltd. Ibuprofen solutions for capsule-filling and capsule preparations
US7138133B2 (en) 2001-10-10 2006-11-21 The Procter & Gamble Company Orally administered liquid compositions
US20070020330A1 (en) 2004-11-24 2007-01-25 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
PT2486942T (pt) 2004-11-24 2019-01-18 Meda Pharmaceuticals Inc Composições que compreendem azelastina e seus métodos de utilização
NZ554779A (en) * 2005-02-01 2011-02-25 Troikaa Pharmaceuticals Ltd Injectable preparations of diclofenac ((2,6-dichloranilino)phenylacetic acid) and its pharmaceutically acceptable salts
JP5529529B2 (ja) 2006-04-05 2014-06-25 インターコンチネンタル グレート ブランズ エルエルシー 口腔輸送システムに用いるリン酸カルシウム錯体及び塩
JP2009532478A (ja) * 2006-04-05 2009-09-10 キャドバリー アダムス ユーエスエー エルエルシー 酸含有菓子組成物中のリン酸カルシウム錯体
PL2076142T3 (pl) * 2006-06-29 2020-05-18 Intercontinental Great Brands Llc Usprawniona przecinarka łańcuchowa do ciągłego formowania kawałków gumy do żucia z nadzieniem
US20090029018A1 (en) * 2007-07-27 2009-01-29 Cadbury Adams Usa Llc Method and apparatus for processing confectionery products
DE102007000521A1 (de) * 2007-10-18 2009-04-23 Renate Conrad Hustenpräparat
ES2393224T5 (es) † 2008-02-08 2020-09-14 Procter & Gamble Proceso para fabricar una bolsa soluble en agua
WO2014037832A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment of epilepsy and neurological diseases
WO2013168021A1 (en) 2012-05-07 2013-11-14 Mahesh Kandula Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders
US9399634B2 (en) 2012-05-07 2016-07-26 Cellix Bio Private Limited Compositions and methods for the treatment of depression
CA2872975A1 (en) 2012-05-07 2013-11-14 Cellixbio Private Limited Compositions and methods for the treatment of neurological disorders
WO2013167993A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurological degenerative disorders
WO2013168025A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of blood clotting disorders
WO2013167992A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of inflammatory disorders
WO2013168023A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of parkinson's disease
WO2013167991A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic disorders
US9394288B2 (en) 2012-05-10 2016-07-19 Cellix Bio Private Limited Compositions and methods for the treatment of asthma and allergy
US9573927B2 (en) 2012-05-10 2017-02-21 Cellix Bio Private Limited Compositions and methods for the treatment of severe pain
US9403857B2 (en) 2012-05-10 2016-08-02 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
WO2013168001A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
US9339484B2 (en) 2012-05-10 2016-05-17 Cellix Bio Private Limited Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
WO2013168002A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurological conditions
WO2013168012A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of respiratory disorders
WO2013167999A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurologic diseases
US9346742B2 (en) 2012-05-10 2016-05-24 Cellix Bio Private Limited Compositions and methods for the treatment of fibromyalgia pain
WO2013168033A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for treatment of neurologic diseases
WO2013168011A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of chronic pain
WO2013168014A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of familial amyloid polyneuropathy
US9315478B2 (en) 2012-05-10 2016-04-19 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
CA2873096A1 (en) 2012-05-23 2013-11-28 Cellixbio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
WO2013175376A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of local pain
CN104583182A (zh) 2012-05-23 2015-04-29 塞利克斯比奥私人有限公司 用于治疗粘膜炎的组合物和方法
JP2015518854A (ja) 2012-05-23 2015-07-06 セリックスビオ プライヴェート リミテッド 多発性硬化症の治療のための組成物および方法
WO2013175347A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of respiratory disorders
US9434729B2 (en) 2012-05-23 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of periodontitis and rheumatoid arthritis
US9108942B1 (en) 2014-11-05 2015-08-18 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
US9187427B2 (en) 2012-08-03 2015-11-17 Cellix Bio Private Limited N-substituted nicotinamide compounds and compositions for the treatment migraine and neurologic diseases
WO2014037833A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment inflammation and lipid disorders
GB201215988D0 (en) * 2012-09-07 2012-10-24 Reckitt Benckiser Healthcare Int Ltd Pharmaceutical compositions comprising flurbiprofen
SG11201407325YA (en) 2012-09-08 2014-12-30 Cellix Bio Private Ltd Compositions and methods for treatment of inflammation and lipid disorders
US9333187B1 (en) 2013-05-15 2016-05-10 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
WO2014195961A1 (en) 2013-06-04 2014-12-11 Mahesh Kandula Compositions and methods for the treatment of diabetes and pre-diabetes
US9096537B1 (en) 2014-12-31 2015-08-04 Mahesh Kandula Compositions and methods for the treatment of mucositis
SG11201706952VA (en) 2014-09-26 2017-10-30 Cellix Bio Private Ltd Compositions and methods for the treatment of epilepsy and neurological disorders
EP3201168B1 (en) 2014-09-29 2020-03-18 Cellix Bio Private Limited Compounds and compositions for the treatment of multiple sclerosis
EP3212626B1 (en) 2014-10-27 2018-11-07 Cellix Bio Private Limited Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis
US9284287B1 (en) 2014-11-05 2016-03-15 Cellix Bio Private Limited Compositions and methods for the suppression of carbonic anhydrase activity
US9321716B1 (en) 2014-11-05 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9173877B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
US9175008B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Prodrugs of anti-platelet agents
US9150557B1 (en) 2014-11-05 2015-10-06 Cellix Bio Private Limited Compositions and methods for the treatment of hyperglycemia
US9290486B1 (en) 2014-11-05 2016-03-22 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy
US10208014B2 (en) 2014-11-05 2019-02-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
US9932294B2 (en) 2014-12-01 2018-04-03 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
EP3229820A4 (en) * 2014-12-12 2018-07-11 Ari Healthcare Pvt. Ltd. A mouth freshener
US9206111B1 (en) 2014-12-17 2015-12-08 Cellix Bio Private Limited Compositions and methods for the treatment of neurological diseases
CN110845355A (zh) 2015-01-06 2020-02-28 塞尔利克斯生物私人有限公司 用于治疗炎症和疼痛的组合物和方法
US11234897B2 (en) * 2017-03-27 2022-02-01 DXM Pharmaceutical, Inc. Packaged multi-dose liquid dextromethorphan hydrobromide formulation
US11911517B2 (en) 2018-05-16 2024-02-27 Bayer Healthcare Llc High concentration suspension formulation for cold and flu soft gel capsule medications

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL272604A (es) * 1960-12-28
US4136163A (en) 1971-02-04 1979-01-23 Wilkinson Sword Limited P-menthane carboxamides having a physiological cooling effect
CA1027347A (en) 1972-07-20 1978-03-07 David G. Rowsell Compounds having a physiological cooling effect and compositions containing them
SE7812207L (sv) 1977-12-01 1979-06-02 Welsh Nat School Med Apparat, forfarande och framstellda produkter for anvendning vid administration av antihistaminer
US4474985A (en) 1981-07-06 1984-10-02 Monsanto Company Purification of N-acetyl aminophenols
JPS5888334A (ja) 1981-11-20 1983-05-26 Takasago Corp ３−ｌ−メントキシプロパン−１、２−ジオ−ル
US4478822A (en) 1983-05-16 1984-10-23 Merck & Co., Inc. Drug delivery system utilizing thermosetting gels
US4474752A (en) 1983-05-16 1984-10-02 Merck & Co., Inc. Drug delivery system utilizing thermosetting gels
GB8629567D0 (en) 1986-12-10 1987-01-21 Boots Co Plc Therapeutic agents
IE59934B1 (en) 1987-06-19 1994-05-04 Elan Corp Plc Liquid suspension for oral administration
US4883660A (en) * 1988-10-17 1989-11-28 Thames Pharmacal Co., Inc. Gel bases for pharmaceutical compositions
US5196486A (en) 1989-03-17 1993-03-23 Nalco Chemical Company Alkoxylated vinyl polymer demulsifiers
US5100898A (en) 1990-01-25 1992-03-31 Richardson-Vicks Inc. Antitussive liquid compositions containing dyclonine
AU663857B2 (en) * 1990-10-31 1995-10-26 Procter & Gamble Company, The Dextromethorphan antitussive compositions
US5196436A (en) 1990-10-31 1993-03-23 The Procter & Gamble Company Dextromethorphan antitussive compositions
US5141961A (en) 1991-06-27 1992-08-25 Richrdson-Vicks Inc. Process for solubilizing difficulty soluble pharmaceutical actives
AU6086794A (en) 1993-02-18 1994-09-14 Warner-Lambert Company Cold/sinus preparation consisting of phenindamine tartarate with or without therapeutic agents
US5505961A (en) 1993-08-05 1996-04-09 R. P. Scherer Corporation Gelatin capsules containing a highly concentrated acetaminophen solution
WO1995019759A1 (en) 1994-01-24 1995-07-27 The Procter & Gamble Company Process for solubilizing difficultly soluble pharmaceutical actives
US5510389A (en) 1994-03-02 1996-04-23 The Procter & Gamble Company Concentrated acetaminophen solution compositions
US5458879A (en) 1994-03-03 1995-10-17 The Procter & Gamble Company Oral vehicle compositions
US5616621A (en) 1995-01-30 1997-04-01 American Home Products Corporation Taste masking liquids
US5846557A (en) * 1996-03-20 1998-12-08 Cumberland Packing Corporation Chewing gum containing cough suppressing agent
US5955098A (en) 1996-04-12 1999-09-21 Flemington Pharmaceutical Corp. Buccal non polar spray or capsule
ES2234010T3 (es) * 1996-04-12 2005-06-16 Novadel Pharma Inc. Aerosol bucal polar.
SE9601528D0 (sv) * 1996-04-23 1996-04-23 Pharmacia Ab Transdermally administered dextromethorphan as antitissue agent
US6027746A (en) * 1997-04-23 2000-02-22 Warner-Lambert Company Chewable soft gelatin-encapsulated pharmaceutical adsorbates
AU7916798A (en) 1997-05-22 1998-12-11 Boots Company Plc, The Pharmaceutical compositions of flurbiprofen and burn-masking agent for treating sore throat
DE69738333T2 (de) 1997-10-01 2008-11-27 Novadel Pharma Inc. Nichtpolares Spray zur bukkalen Verabreichung

Also Published As

Publication number Publication date
HUP0105021A3 (en) 2003-02-28
KR20010093255A (ko) 2001-10-27
CA2356881C (en) 2012-02-28
AU762366B2 (en) 2003-06-26
US6846495B2 (en) 2005-01-25
CZ20012491A3 (cs) 2001-12-12
HUP0105021A2 (hu) 2002-05-29
US20030139437A1 (en) 2003-07-24
JP2002534463A (ja) 2002-10-15
CA2356881A1 (en) 2000-07-20
BR0007445A (pt) 2001-10-16
AU2962700A (en) 2000-08-01
TR200101927T2 (tr) 2001-11-21
WO2000041693A2 (en) 2000-07-20
EP1140093A2 (en) 2001-10-10
NO20013442L (no) 2001-09-11
CN1203854C (zh) 2005-06-01
CN1336823A (zh) 2002-02-20
NO20013442D0 (no) 2001-07-11
KR100511730B1 (ko) 2005-08-31
CO5270007A1 (es) 2003-04-30
WO2000041693A3 (en) 2000-11-30

Similar Documents

Publication Publication Date Title
PE20001415A1 (es) Composiciones que tienen suministro mejorado de activos
PE20010627A1 (es) Composiciones que tienen estabilidad mejorada
PE20110010A1 (es) Formulaciones liquidas de fenilefrina
US8808755B2 (en) Hydrogen peroxide-based skin disinfectant
PE20060375A1 (es) Formas farmaceuticas orales, protegidas frente al abuso
ES2584858T3 (es) Composiciones farmacéuticas acuosas que contienen complejos de borato-poliol
PE20050175A1 (es) Peliculas consumibles oralmente de disolucion rapida que contienen un almidon modificado para la mejora de la resistencia al calor y a la humedad
ES2091441T3 (es) Composicion farmaceutica.
JP2005510538A5 (es)
AR037490A1 (es) Composiciones farmaceuticas solidas, proceso para su preparacion, kit para el tratamiento de la obesidad y uso de dichas composiciones en la elaboracion de medicamentos
UY28067A1 (es) Formulaciones de deposito de liberacion controlada
AR051404A1 (es) Composiciones de limpieza y desinfectantes
ES2664975T3 (es) Películas hidrosolubles que comprenden alginatos de baja viscosidad
AR029456A1 (es) Forma triturada
BR112019000849B1 (pt) Composições líquidas de limpeza com sistema antibacteriano e método de fabricação das mesmas
CO6300926A2 (es) Composicion dentifrica que contiene un hidrocoloide, un polisacarido, un copolimero y una fuente de ion de fluoruro
PE20150773A1 (es) Composiciones farmaceuticas para la liberacion sostenida de fenilefrina
AR095159A2 (es) Una composición farmacéutica en forma de cápsula para administración oral
PE20001424A1 (es) Composiciones que tienen estabilidad mejorada
CO5430216A1 (es) Composiciones que tienen estabilidad mejorada de activos farmaceuticos
JP2024028391A5 (es)
ES2699711T3 (es) Composiciones farmacéuticas encapsuladas en gelatina blanda que comprenden ingredientes activos concentrados
ECSP045110A (es) Composiciones de la preparación que contiene un compuesto fisiologicamente activo de acidos inestables y procesos para su producción
ATE528009T1 (de) Reepithelialisierende pharmazeutische zusammensetzungen, die xanthangummi enthalten
CO5540295A2 (es) Comprimido para tragar que comprende paracetamol

Legal Events

Date Code Title Description
FC Refusal